The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Brivaracetam
Brivaracetam Injection · BRIVARACETAM 50 mg/5mL · Injection · Intravenous · PAI Holdings, LLC dba PAI Pharma
NDC 00121-1075-02 · 10 VIAL, GLASS in 1 CARTON / 5 mL in 1 VIAL, GLASS · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA218249
- TE code
- AP
- Approval date
- Feb 23, 2026
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Brivaracetam Injection (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| PAI Holdings, LLC dba PAI Pharma | BRIVARACETAM 50 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Brivaracetam — NDC 00121-1075-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00121107502.
Free to cite with attribution — see how the data is put together.